Wednesday, June 17, 2009

Microbiota in IBS

*As Irritable Bowel Syndrome may be co-morbid in some subgroups of patients
with ME or the ME/CFS this study documenting  immune factors and a
post-infectious variable adds to the biomedical literature. However, another
factor regarding IBS that should be noted is possible misdiagnosis of IBS
because common gastrointestinal symptoms of OI are misinterpreted.

* *Am J Gastroenterol 2008
Jun;103(6):1557-67. Epub 2008 May
Gastrointestinal microbiota in irritable bowel syndrome: their role in its
pathogenesis and treatment. *Parkes
GC* ,
*Brostoff J*,
*Whelan K* ,
*Sanderson JD*

Diet and Gastrointestinal Health, Nutritional Sciences Division, King's
College London, London, United Kingdom.

Irritable bowel syndrome (IBS) is a chronic disorder characterized by
abdominal pain, change in bowel habit, and bloating. It has traditionally
been viewed as a disorder of visceral hypersensitivity heavily influenced by
stress, and therefore therapeutic strategies to date have largely reflected

However, more recently, there is good evidence for a role of the
gastrointestinal (GI) microbiota in its pathogenesis. Changes in fecal
microbiota, the use of probiotics, the phenomenon of postinfectious IBS, and
the recognition of an upregulated host immune system response suggest that
an interaction between the host and GI microbiota may be important in the
pathogenesis of IBS.

This article explores the role of the GI microbiota in IBS and how their
modification might lead to therapeutic benefit.


No comments: